Patients undergoing atrial fibrillation (AFib) ablation who were not properly anticoagulated and did not undergo preprocedural transesophageal echocardiogram (TEE) were significantly more likely to ...

Compared with oral anticoagulant (OAC)-experienced patients, OAC-naïve patients received the same benefit in decreased bleeding risk with asundexian vs. apixaban but they were also less likely to ...

More patients who received the Watchman 2.5 device compared with the Amulet occluder device for left atrial appendage occlusion experienced high-risk device-related thrombi (DRTs), according to a ...

Transcatheter tricuspid valve replacement (TTVR) may be a "feasible and effective approach" for treating high-risk patients with severe tricuspid regurgitation (TR) who have limited therapeutic ...

An early one-time simultaneous measurement of LDL-C, high-sensitivity C-reactive protein (hsCRP) and lipoprotein(a) (Lp[a]) can independently predict long-term cardiovascular risk, according to a ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

Transcatheter aortic valve implantation (TAVI) was superior to surgical aortic valve replacement (SAVR) in women with severe aortic stenosis (AS), according to results from the RHEIA trial published ...

Join ACC's Prevention of Cardiovascular Disease Member Section this Wednesday, April 9 at 1 p.m. ET for a recap of ACC.25 prevention content and its influence on clinical practice. The webinar will ...

A 21-year-old male collegiate football player presents for an annual physical examination with blood pressure (BP) elevated to 147/82 mm Hg. He is counseled on lifestyle modifications, including the ...

A program that delivered in-home visits from a trained paramedic team to people with heart failure did not significantly reduce 30-day hospital readmissions or improve health status compared with ...

Patients who were counseled on heart medications and lifestyle modifications by specially trained nurses were 30% less likely to experience cardiovascular death, heart attack or stroke five years ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to experience cardiovascular death, heart attack or stroke ...